Proteolysis-targeting chimeras in breast cancer therapy

References

• 1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J. Clin. 70(1), 7–30 (2020).
  MedlineGoogle Scholar
• 2. Liu J, Ma J, Liu Y et al. PROTACs: a novel strategy for cancer therapy. Semin. Cancer Biol. doi.org/10.1016/j.semcancer.2020.02.006 (2020) (Epub ahead of print).
  Google Scholar
• 3. Du J, Guo J, Kang D et al. New techniques and strategies in drug discovery. Chin. Chem. Lett. 31, 1695–1708 (2020).
  CASGoogle Scholar
• 4. Zou Y, Ma D, Wang Y. The PROTAC technology in drug development. Cell Biochem. Funct. 37(1), 21–30 (2019).
  Medline CASGoogle Scholar
• 5. Itoh Y. Chemical protein degradation approach and its application to epigenetic targets. Chem. Rec. 18(12), 1681–1700 (2018).
  Medline CASGoogle Scholar
• 6. Paiva SL, Crews CM. Targeted protein degradation: elements of PROTAC design. Curr. Opin. Chem. Biol. 50, 111–119 (2019).
  Medline CASGoogle Scholar
• 7. Borsari C, Trader DJ, Tait A et al. Designing chimeric molecules for drug discovery by leveraging chemical biology. J. Med. Chem. 63(5), 1908–1928 (2020).
  Medline CASGoogle Scholar
• 8. Lu J, Qian Y, Altieri M et al. Hijacking the E3 ubiquitin ligase cereblon to efficiently target BRD4. Chem. Biol. 22(6), 755–763 (2015).
  Medline CASGoogle Scholar
• 9. Wang Y, Jiang X, Feng F et al. Degradation of proteins by PROTACs and other strategies. Acta Pharm. Sin. B. 10(2), 207–238 (2020).
  Medline CASGoogle Scholar
• 10. Li X, Song Y. Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy. J. Hematol. Oncol. 13(1), 50 (2020).
  MedlineGoogle Scholar
• 11. Chamberlain PP, Hamann LG. Development of targeted protein degradation therapeutics. Nat. Chem. Biol. 15(10), 937–944 (2019).
  Medline CASGoogle Scholar
• 12. Li W, Bengtson MH, Ulbrich A et al. Genome-wide and functional annotation of human E3 ubiquitin ligases identifies MULAN, a mitochondrial E3 that regulates the organelle's dynamics and signaling. PLoS ONE 3(1), e1487 (2008).
  MedlineGoogle Scholar
• 13. Zhao Q, Lan T, Su S et al. Induction of apoptosis in MDA-MB-231 breast cancer cells by a PARP1-targeting PROTAC small molecule. Chem. Commun. (Camb). 55(3), 369–372 (2019).
  Medline CASGoogle Scholar
• 14. Hu J, Hu B, Wang M et al. Discovery of ERD-308 as a highly potent proteolysis targeting chimera (PROTAC) degrader of estrogen receptor (ER). J. Med. Chem. 62(3), 1420–1442 (2019).
  Medline CASGoogle Scholar
• 15. Smith BE, Wang SL, Jaime-Figueroa S et al. Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase. Nat. Commun. 10(1), 131 (2019).
  MedlineGoogle Scholar
• 16. Liu Y, Zhen Y, Wang G et al. Designing an eEF2K-targeting PROTAC small molecule that induces apoptosis in MDA-MB-231 cells. Eur. J. Med. Chem. 204, 112505 (2020).
  Medline CASGoogle Scholar
• 17. Noblejas-López MDM, Nieto-Jimenez C, Burgos M et al. Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer. J. Exp. Clin. Cancer Res. 38(1), 383 (2019).
  MedlineGoogle Scholar
• 18. Burslem GM, Smith BE, Lai AC et al. The advantages of targeted protein degradation over inhibition: an RTK case study. Cell Chem. Biol. 25(1), 67–77 (2018).
  Medline CASGoogle Scholar